Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

SSTR (Somatostatin Receptor)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	lutetium Lu 177 dotatate Sensitive: A1 - Approval lutetium Lu 177 dotatate Sensitive : A1	lutetium Lu 177 dotatate Sensitive: A1 - Approval lutetium Lu 177 dotatate Sensitive : A1
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline lanreotide prolonged-release subcutaneous Sensitive : A2	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline lanreotide prolonged-release subcutaneous Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	CAPTEM Sensitive: A2 - Guideline CAPTEM Sensitive : A2	CAPTEM Sensitive: A2 - Guideline CAPTEM Sensitive : A2
SSTR Expression	Neuroendocrine Tumor	SSTR Expression	Neuroendocrine Tumor	ORM-2110 Sensitive: C3 – Early Trials ORM-2110 Sensitive : C3	ORM-2110 Sensitive: C3 – Early Trials ORM-2110 Sensitive : C3
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	RYZ101 Sensitive: C3 – Early Trials RYZ101 Sensitive : C3	RYZ101 Sensitive: C3 – Early Trials RYZ101 Sensitive : C3